Literature DB >> 32007209

International standards for the analysis of quality-of-life and patient-reported outcome endpoints in cancer randomised controlled trials: recommendations of the SISAQOL Consortium.

Corneel Coens1, Madeline Pe2, Amylou C Dueck3, Jeff Sloan4, Ethan Basch5, Melanie Calvert6, Alicyn Campbell7, Charles Cleeland8, Kim Cocks9, Laurence Collette1, Nancy Devlin10, Lien Dorme1, Hans-Henning Flechtner11, Carolyn Gotay12, Ingolf Griebsch13, Mogens Groenvold14, Madeleine King15, Paul G Kluetz16, Michael Koller17, Daniel C Malone18, Francesca Martinelli1, Sandra A Mitchell19, Jammbe Z Musoro1, Daniel O'Connor20, Kathy Oliver21, Elisabeth Piault-Louis22, Martine Piccart23, Chantal Quinten24, Jaap C Reijneveld25, Christoph Schürmann26, Ashley Wilder Smith19, Katherine M Soltys27, Martin J B Taphoorn28, Galina Velikova29, Andrew Bottomley1.   

Abstract

Patient-reported outcomes (PROs), such as symptoms, function, and other health-related quality-of-life aspects, are increasingly evaluated in cancer randomised controlled trials (RCTs) to provide information about treatment risks, benefits, and tolerability. However, expert opinion and critical review of the literature showed no consensus on optimal methods of PRO analysis in cancer RCTs, hindering interpretation of results. The Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data Consortium was formed to establish PRO analysis recommendations. Four issues were prioritised: developing a taxonomy of research objectives that can be matched with appropriate statistical methods, identifying appropriate statistical methods for PRO analysis, standardising statistical terminology related to missing data, and determining appropriate ways to manage missing data. This Policy Review presents recommendations for PRO analysis developed through critical literature reviews and a structured collaborative process with diverse international stakeholders, which provides a foundation for endorsement; ongoing developments of these recommendations are also discussed.
Copyright © 2020 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2020        PMID: 32007209     DOI: 10.1016/S1470-2045(19)30790-9

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN: 1470-2045            Impact factor:   41.316


  47 in total

1.  Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.

Authors:  Gita Thanarajasingam; John P Leonard; Thomas E Witzig; Thomas M Habermann; Kristie A Blum; Nancy L Bartlett; Christopher R Flowers; Brandelyn N Pitcher; Sin-Ho Jung; Pamela J Atherton; Angelina Tan; Paul J Novotny; Amylou C Dueck
Journal:  Lancet Haematol       Date:  2020-06       Impact factor: 18.959

Review 2.  What is the future of patient-reported outcomes in sickle-cell disease?

Authors:  Sharon A Singh; Nitya Bakshi; Prashant Mahajan; Claudia R Morris
Journal:  Expert Rev Hematol       Date:  2020-10-15       Impact factor: 2.929

Review 3.  Understanding Health-Related Quality of Life in Patients with Mantle Cell Lymphoma.

Authors:  Priyanka A Pophali; Gita Thanarajasingam
Journal:  Hematol Oncol Clin North Am       Date:  2020-08-05       Impact factor: 3.722

4.  Patient-reported outcomes in non-muscle invasive bladder cancer: a mixed-methods systematic review.

Authors:  Claudia Rutherford; Manish I Patel; Margaret-Ann Tait; David P Smith; Daniel S J Costa; Shomik Sengupta; Madeleine T King
Journal:  Qual Life Res       Date:  2020-09-22       Impact factor: 4.147

5.  Quality of patient-reported outcome reporting according to the CONSORT statement in randomized controlled trials with glioblastoma patients.

Authors:  Louis Garnier; Emilie Charton; Antoine Falcoz; Sophie Paget-Bailly; Dewi Vernerey; Marine Jary; François Ducray; Elsa Curtit
Journal:  Neurooncol Pract       Date:  2020-11-11

Review 6.  Patient-reported outcomes in vaccines research: relevance for decision-making.

Authors:  Desmond Curran; Eliazar Sabater Cabrera; Linda Nelsen
Journal:  Hum Vaccin Immunother       Date:  2021-02-19       Impact factor: 3.452

7.  Patient-Reported Outcomes Predict Progression-Free Survival of Patients with Advanced Breast Cancer Treated with Abemaciclib.

Authors:  Sarah Badaoui; Ganessan Kichenadasse; Andrew Rowland; Michael J Sorich; Ashley M Hopkins
Journal:  Oncologist       Date:  2021-05-11

Review 8.  Late Effects after Chimeric Antigen Receptor T cell Therapy for Lymphoid Malignancies.

Authors:  Rajshekhar Chakraborty; Brian T Hill; Aneela Majeed; Navneet S Majhail
Journal:  Transplant Cell Ther       Date:  2020-12-21

9.  Patient-Reported Outcomes in Clinical Trials Leading to Cancer Immunotherapy Drug Approvals From 2011 to 2018: A Systematic Review.

Authors:  Houssein Safa; Monica Tamil; Philippe E Spiess; Brandon Manley; Julio Pow-Sang; Scott M Gilbert; Firas Safa; Brian D Gonzalez; Laura B Oswald; Adele Semaan; Adi Diab; Jad Chahoud
Journal:  J Natl Cancer Inst       Date:  2021-05-04       Impact factor: 13.506

Review 10.  Patient-Reported Outcomes Associated with Treatments for Testicular Cancer: A Systematic Review.

Authors:  Rebecca Mercieca-Bebber; Sayeda Kamrun Naher; Orlando Rincones; Allan Ben Smith; Martin R Stockler
Journal:  Patient Relat Outcome Meas       Date:  2021-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.